Regeneron Pharmaceuticals, Inc. announced that On January 26, 2024, the Company also appointed Jason Pitofsky, currently the Company?s Vice President, Accounting and Financial Reporting, as Vice President, Controller. Each such appointment will be effective as of the day after Regeneron files its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (expected to occur on February 5, 2024).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
973.8 USD | +0.60% | +1.76% | +10.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.87% | 105B | |
+3.91% | 109B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B | |
+295.70% | 8.12B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024